A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
← catalyst calendarNCT07241104 · readout in 460 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
31estimated
Sites
4
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-01 | actual | When the study began enrolling |
| Primary completion | 2027-11-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-22 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dilated Cardiomyopathy
Intervention
- Drug: AZD4063
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Cohort 1 (SAD): From Day 1 to Day 109, Cohorts 2 and 3 (SAD) From Day 1 to Day 99; For Cohorts 1,2 and 3 (MAD): Day 1 to Day 155
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed